Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …

Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …

Objective Rates of worsening and evolution to secondary progressive multiple sclerosis
(MS) may be substantially lower in actively treated patients compared to natural history …

In this study (trial registration: NCT02166021), we aimed to evaluate the optimal way of
administration, the safety and the clinical efficacy of mesenchymal stem cell (MSC) …

Objective To characterize the accrual of long‐term disability in a cohort of actively treated
multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance …

A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to
detect MS progression. It provides important data for physicians on their daily practice as …

Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …

Despite important advances in the treatment of multiple sclerosis (MS) over recent years, the
introduction of several disease-modifying therapies (DMTs), the burden of progressive …